Feedback
Settings

Settings

Goto Application

25,288 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

IPC=A61K
1 / 2,529
1.1020210048608다형교모세포종 및 수모세포종을 비롯한 신생종양 질환 및 암 줄기세포의 치료를 위한 디안히드로갈락티톨 및 유사체를 비롯한 치환된 헥시톨의 용도
KR - 03.05.2021
Int.Class A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
 Appl.No 1020217012517 Applicant 브라운, 데니스, 엠. Inventor 바차, 제프리
디안히드로갈락티톨의 사용은 다형교모세포종 및 수모세포종의 치료에 있어서 새로운 치료학적 방법론을 제공한다. 디안히드로갈락티톨은 N 메틸화를 생성하는 DNA에 대해 알킬화제로서 작용한다. 디안히드로갈락티톨은 암 줄기세포의 성장을 억제하는데 효과적이고 테모졸로마이드로는 난치성인 종양에 대해 활성적이며; 이 약물은 MGMT 복구 메카니즘과는 독립적으로 작용한다. 7
2.104427984Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
CN - 18.03.2015
Int.Class A61K 31/35
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
 Appl.No 201380015319.5 Applicant BROWN DENNIS Inventor BACHA JEFFREY
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
3.4959215Ifosfamide-mesna lyophilizate and process for its preparation
US - 25.09.1990
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
 Appl.No 07325883 Applicant Asta Pharma AG Inventor Sauerbier Dieter

An ifosfamide-mesna lyophilizate consists substantially of ifosfamide, 0.1-1.0 parts by weight of mesna and 0.1 to 17 parts by weight of hexitol. The product is obtained by freeze drying an aqueous or aqueous-ethanolic solution of ifosfamide and mesna.

4.115778934Use of substituted hexitols for treatment of malignancies
CN - 14.03.2023
Int.Class A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
 Appl.No 202211320632.7 Applicant DERMA CO., LTD. Inventor BASHA JEFFREY
The present invention relates to the use of substituted hexitols for the treatment of malignancies. The use of dianhydrogalactitol provides a novel way of treatment to treat glioblastoma multiforme and neuroblastoma. The dianhydrogalactitol is used as an alkylating agent to act on DNA (deoxyribonucleic acid) to cause N7 methylation. The dianhydrogalactitol is effective in inhibiting the growth of cancer stem cells and has the activity of resisting temozolomide-resistant tumors; the drug effect is irrelevant to MGMT repair mechanism.
5.110711188Use of substituted hexitols to treat malignant tumors
CN - 21.01.2020
Int.Class A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
 Appl.No 201910649595.6 Applicant DELMAR PHARMACEUTICALS INC. Inventor BACHA JEFFREY
Use of substituted hexitols to treat malignant tumors. The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
6.115813902Use of substituted hexitols for treatment of malignancies
CN - 21.03.2023
Int.Class A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
 Appl.No 202211319179.8 Applicant DERMA CO., LTD. Inventor BASHA JEFFREY
The present invention relates to the use of substituted hexitols for the treatment of malignancies. The use of dianhydrogalactitol provides a novel way of treatment to treat glioblastoma multiforme and neuroblastoma. The dianhydrogalactitol is used as an alkylating agent to act on DNA (deoxyribonucleic acid) to cause N7 methylation. The dianhydrogalactitol is effective in inhibiting the growth of cancer stem cells and has the activity of resisting temozolomide-resistant tumors; the drug effect is irrelevant to MGMT repair mechanism.
7.1020160132130폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
KR - 16.11.2016
Int.Class A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
 Appl.No 1020167030879 Applicant 델 마 파마슈티컬스 Inventor 바차, 제프리, 에이.
디안하이드로갈락티톨의 사용은 비소세포 폐암종(NSCLC) 및 난소암의 치료를 위한 새로운 치료 양식을 제공한다. 디안하이드로갈락티톨은 DNA에 N 메틸화를 생성하는 알킬화제로서 작용한다. 디안하이드로갈락티톨은 암 줄기세포의 성장을 억제하는데 유효하고, 테모졸로미드, 시스플라틴, 및 티미딘 키나제 저해제에 대해 난치성인 종양에 대하여 활성이 있다; 이 약물은 MGMT 복구 메커니즘와 독립적으로 작용한다. 디안하이드로갈락티톨 다른 항신생물제와 함께 사용될 수 있으며, 부가적 또는 초부가적 효과를 가질 수 있다. 7
8.WO/2022/174053LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF
WO - 18.08.2022
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No PCT/US2022/016143 Applicant IONIS PHARMACEUTICALS, INC. Inventor PRAKASH, Thazha, P.
The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one chemical modification.
9.1020160065776재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를 위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도
KR - 09.06.2016
Int.Class A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
 Appl.No 1020157037286 Applicant 델 마 파마슈티컬스 인코포레이티드 Inventor 브라운, 데니스, 엠.
재발성 신경교종 및 진행성 2차 뇌종양과 같은 악성 종양의 치료에 적합한 방법 및 조성물이 개시된다. 이들 방법은 디안히드로갈락티톨, 디안히드로갈락티톨의 유도체 또는 유사체, 디아세틸디안히드로갈락티톨, 또는 디아세틸디안히드로갈락티톨의 유도체 또는 유사체와 같은 헥시톨 유도체를 사용한다. 조성물은 이러한 헥시톨 유도체를 포함할 수 있다.
10.WO/2001/091741COMPOSITIONS CONTAINING HEXITOL AND AN ANTIPROLIFERATIVE AGENT
WO - 06.12.2001
Int.Class A61K 31/70
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
 Appl.No PCT/US2001/017789 Applicant CHEMGENEX THERAPEUTICS, INC. Inventor BROWN, Dennis, M.
A method of treatment of a host with a cellular proliferative disease, comprising contacting the host with a hexitol and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, is described. In some embodiments, the hexitol comprises dianhydrogalactitol (Dianhydrodulcitol; Dulcitol diepoxide; DAD; DAG; 5,6-Diepoxydulcitol; 1,2:5,6-Dianhydrodulcitol; 1,2:5,6-Dianhydrogalactitol; 1,2;5,6-Diepoxydulcitol). Antiproliferative agents of the invention comprise alkylating agents, intercalating agents, metal coordination complexes, pyrimidine nucleosides, purine nucleosides, inhibitors of nucleic acid associated enzymes and proteins, and agents affecting structural proteins and cytoplasmic enzymes. The invention comprises the described methods as well as compositions comprising a hexitol and an antiproliferative agent.
# -